European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Epivir, lamivudine, Date of authorisation: 08/08/1996, Revision: 51, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 14:44

Human medicines European public assessment report (EPAR): Epivir, lamivudine, Date of authorisation: 08/08/1996, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 14:37

Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 13:54

Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 13:44

Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 20 August 2026 - 13:07

Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 20, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More